AGC (5201) FY2025 FY Earnings Report

Quick View

Executive Summary

Net income turned substantially profitable due to the rebound from the previous year's massive impairment loss; however, the improvement in the profitability of the core business was gradual, and the absence of a revenue growth trend was a key feature of the current-period results. Revenue was ¥20588.3B (-0.4% YoY), operating income was ¥1274.7B (+1.3% YoY), and consolidated net income was ¥794.7B (versus a loss of ¥779.2B in the previous year). Net income attributable to owners of the parent was ¥691.6B, recovering from a loss of ¥940.4B in the previous year. The primary driver of profit growth was a substantial improvement in profitability in Automotive, while Electronics and Chemicals posted lower profits and Life Science remained loss-making, resulting in divergent performance across businesses.

Factors Affecting Performance

【Revenue】Revenue was ¥20588.3B, essentially flat at -0.4% YoY. While Automotive increased revenue by +4.4% and Building Glass by +0.7%, Electronics (-2.6%), Chemicals (-1.7%), and Life Science (-5.8%) reported lower revenue, resulting in a slight decline in company-wide revenue.

【Profit and Loss】Operating income was ¥1274.7B (+1.3% YoY), supported by an improvement in the gross profit margin to 24.3% (24.1% in the previous year) and a decrease in SG&A expenses (¥3749.8B versus ¥3756.8B in the previous year). Profit before tax was ¥1247.6B, a substantial improvement from the previous year's loss of ¥502.6B; however, this improvement was largely attributable to the temporary effect of the reversal of the large impairment loss (¥1247.7B) recorded under other expenses in the previous year. An impairment loss of ¥96.9B also remained in the current period. Net income was broadly consistent with profit at the ordinary-income stage, with no significant divergence. Although both revenue declines with profit growth and revenue growth with profit declines were present across businesses, the company-wide result can be concluded to be a revenue decline with profit growth.

Segment Analysis

By operating income composition, Chemicals was the largest segment at ¥530.4B, accounting for approximately 41.6%, and is positioned as the core business. However, Chemicals reported a 6.6% YoY decline in profit, affected by weak PVC market conditions. The largest driver of profit growth was Automotive, which posted operating income of ¥293B, a substantial 110.2% YoY increase, supported by an improved product mix and the effects of pricing policies. Life Science continued to report an operating loss of ¥222.6B (profit margin of -17.2%), affected by the lapping of temporary revenue from the biopharmaceutical CDMO business and site closure costs. Electronics had the highest profit margin among all segments at 13.5%, but profit declined 12.7% YoY due to factors including lower shipments of EUV mask blanks, and the significant disparity in profit margins among segments continued.

Key Financial Metrics

Profitability: ROE 4.7%, operating margin 6.2% (6.1% in the previous year)
Cash quality: Operating CF / net income attributable to owners of the parent 3.97x, FCF (Operating CF + Investing CF) ¥960.7B
Investment efficiency: Capital expenditures / depreciation and amortization 1.40x (a growth-investment phase exceeding replacement investment)
Financial soundness: Equity Ratio 50.3% (49.7% in the previous year)

Cash Flow Analysis

Operating CF was ¥2744.8B, or 3.97x net income attributable to owners of the parent of ¥691.6B, indicating strong cash backing for earnings. Investing CF was -¥1784.0B, primarily due to capital expenditures of ¥2512.8B, partially offset by proceeds from the sale of property, plant and equipment of ¥305.2B. Financing CF was -¥1140.5B, mainly reflecting dividend payments of ¥445.9B and borrowing and repayment of interest-bearing debt. FCF was ¥960.7B, covering dividend payments by 2.15x. Cash generation is assessed as standard to moderately strong.

Earnings Quality

The difference between profit before tax of ¥1247.6B and net income of ¥794.7B was ¥452.9B in income taxes and other taxes, resulting in a relatively high effective tax rate of approximately 36.3%. The improvement from the previous year was primarily due to the reduction in other expenses (from ¥1877.5B in the previous year to ¥307.4B in the current period), with most of this difference attributable to the temporary effect of the reversal of the previous year's large impairment loss of ¥1247.7B. It should be noted that an impairment loss of ¥96.9B remained in the current period. Operating CF substantially exceeded net income and net income attributable to owners of the parent, indicating good earnings quality from an accrual perspective. The ¥103.1B difference between consolidated net income of ¥794.7B and net income attributable to owners of the parent of ¥691.6B represents the allocation to non-controlling interests; the two figures should be clearly distinguished without conflation.

Earnings Forecast and Guidance

Using the current-period full-year results as the base year for the new plan, the company's forecast for the next period is revenue of ¥22000B (+6.9%), operating income of ¥1500B (+17.7%), and net income of ¥900B (+11.3%). From the perspective of progress against the forecast, current-period actual results correspond to 93.6% of next-period forecast revenue and 85.0% of next-period forecast operating income. The next period assumes an improvement in operating margin of approximately 60bp (from 6.2% to approximately 6.8%). Achieving this target will depend on the recovery of Life Science and the continued profit growth of Automotive.

Shareholder Returns

The annual dividend was ¥210 per share (¥105 interim and ¥105 year-end), doubling from ¥105 in the previous year. The Payout Ratio was 64.4% (dividend payments of ¥445.9B ÷ net income attributable to owners of the parent of ¥691.6B). Share buybacks were minimal at ¥0.1B, and the Total Return Ratio remained at approximately the same level as the Payout Ratio. Although the Payout Ratio is slightly above the general sustainability benchmark of 60%, FCF of ¥960.7B exceeded dividends, securing near-term dividend capacity from a cash flow perspective.

Catalysts

【Short Term】Progress toward profitability in the Life Science business and trends in improving inventory turnover (inventories of ¥4654.1B). 【Long Term】Progress in structural earnings reforms from 2027 onward aimed at achieving ROE above 8%, as well as the sustainability of profit margins in Chemicals (Southeast Asian PVC market conditions) and Automotive.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Return on equity, operating margin, and net profit margin were all below the industry median, indicating that profitability is relatively low within the industry.

Growth and Capital Efficiency

The revenue growth rate was also substantially below the industry median, indicating that the company's ability to expand its top line compares unfavorably within the industry.

※Source: Compiled by the Company

Risk Factors

1. Continued losses in the Life Science business: The operating loss of ¥222.6B and profit margin of -17.2% have continued. If order growth in the biopharmaceutical CDMO business does not progress as planned, there is a risk that the profitability plan (from 2027 onward) will be delayed.

2. Deterioration in inventory efficiency: Inventories increased by ¥112.7B YoY to ¥4654.1B, accounting for 15.8% of total assets. Market fluctuations may create risks of valuation losses and deterioration in working capital.

3. Market dependence of the core Chemicals business: Chemicals has the largest share of operating income, at approximately 41.6%, but profit declined 6.6% YoY due to weak PVC and caustic soda market conditions in Southeast Asia. A delayed market recovery could affect company-wide profit.

Key Takeaways from the Earnings Results

1. The sharp recovery in net income in the current period was largely attributable to the temporary effect of the reversal of the previous year's large impairment loss of ¥1247.7B. It is therefore important when evaluating earnings quality that the operating margin, which reflects the profitability of the core business, improved only 10bp YoY to 6.2%.

2. Profit margins varied significantly among segments, with most remaining in the single digits except Electronics (13.5%). The contrasting trends of profit growth in Automotive and continued losses in Life Science are attracting attention as a potential inflection point for the company's overall earnings structure.

3. The dividend doubled YoY to ¥210, but the Payout Ratio was relatively high at 64.4%. Monitoring sustainability in light of FCF coverage of 2.15x is therefore useful.

Theoretical Share Price (Reference Value)

Sensitivity: ¥6,168–¥6,519 at ±1% for the cost of equity, and ¥6,318–¥6,354 at ±0.1 for ω.

Notes:

• Net income is substantially compressed relative to operating income due to tax expenses, acquisition-related costs, and non-controlling interests (net income ÷ operating income 51%). This value reflects that compression at face value; if these factors are temporary, underlying earnings power may be higher.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated through an integrated AI analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---